Daily Endocrinology Research Analysis
Analyzed 84 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology papers stand out today: a mechanistic mouse study reveals that exclusive breastfeeding imprints AMPK-dependent thermogenic memory in brown fat via a breast milk EV miR-125a-5p–HIF1AN/AMPK/αKG axis, offering durable metabolic protection. A large, double-blinded, non-selection study shows that reporting putative PGT-A mosaicism adds no predictive value for live birth, challenging current IVF embryo selection practices. The IDF Diabetes Atlas 11th edition projects 589 million adults with diabetes in 2024, rising to ~853 million by 2050, underscoring the urgency of tailored prevention.
Research Themes
- Metabolic programming and thermogenic memory via breastfeeding
- Reproductive endocrinology and embryo genetics: clinical utility of PGT-A mosaicism reporting
- Global diabetes epidemiology and projections for 2050
Selected Articles
1. Exclusive Breastfeeding Drives AMPK-Dependent Thermogenic Memory in BAT and Promotes Long-Term Metabolic Benefits in Offspring.
In mice, exclusive breastfeeding imprints a durable AMPK- and α-ketoglutarate–dependent thermogenic program in brown adipose tissue via breast milk EV miR-125a-5p targeting HIF1AN. This thermogenic memory confers long-term resistance to diet-induced obesity and glucose intolerance; AMPK inhibition abrogates these benefits and αKG supplementation rescues impaired BAT in mixed-fed mice.
Impact: This study uncovers a previously unrecognized, mechanistic link between exclusive breastfeeding and long-term metabolic health through a defined HIF1AN/AMPK/αKG axis in BAT. It provides actionable molecular targets (AMPK, αKG, EV-miR-125a-5p) for metabolic programming.
Clinical Implications: Reinforces recommendations for exclusive breastfeeding as a metabolic preventive strategy and nominates AMPK/αKG and milk EV miRNAs as translational targets for obesity and insulin resistance prevention.
Key Findings
- Mixed formula feeding impaired BAT morphology, mitochondria, and thermogenesis, increasing adiposity and glucose intolerance under HFD.
- Exclusive breastfeeding preserved BAT thermogenic function for up to 12 weeks post-transplant and sustained AMPK activation.
- Breast milk EV miR-125a-5p targeted HIF1AN, enhancing AMPK signaling; AMPK inhibition abolished benefits.
- AMPK-induced α-ketoglutarate was essential for BAT thermogenesis; αKG supplementation rescued BAT defects in mixed-fed mice.
Methodological Strengths
- Comprehensive mechanistic approach including transplantation, transcriptomics, pharmacological inhibition, and metabolite rescue.
- Multiple independent in vivo validations across feeding paradigms with convergent molecular evidence (EV miRNA targeting).
Limitations
- Preclinical mouse model; human generalizability and dose-response of EV miRNAs remain untested.
- Sample sizes and sex-specific effects are not detailed in the abstract; long-term safety of αKG supplementation requires evaluation.
Future Directions: Prospective human studies to test breastfeeding-associated BAT programming markers (AMPK/αKG signatures, EV miR-125a-5p) and interventional trials targeting AMPK/αKG pathways for metabolic disease prevention.
Exclusive breastfeeding reduces the risk of childhood obesity, potentially through metabolic programming of adipose tissue during lactation. However, the underlying mechanisms remain unclear. Using a mouse model, it is shown that mixed formula feeding disrupts brown adipose tissue (BAT) morphology, mitochondrial integrity, and thermogenic capacity, resulting in greater fat accumulation and glucose intolerance after weaning under a high-fat diet. By contrast, BAT from exclusively breastfed mice preserved enhanced thermogenic function for up to 12 weeks after transplantation into recipient mice. Transcriptomic analysis revealed that AMPK activation is sustained in BAT from exclusively breastfed mice but markedly diminished in mixed-fed counterparts. Pharmacological inhibition of AMPK abolished the long-term metabolic benefits conferred by exclusive breastfeeding. Mechanistically, breast milk-derived extracellular vesicles enriched in miR-125a-5p enhanced AMPK signaling by targeting HIF1AN. AMPK-induced α-ketoglutarate (αKG) production proved essential for BAT development and thermogenesis, and αKG supplementation rescued impaired BAT function in mixed-fed mice. In conclusion, exclusive breastfeeding imprints a thermogenic memory in BAT via the HIF1AN/AMPK/αKG signaling axis, thereby conferring long-term metabolic protection to offspring.
2. PGT-A Mosaicism Reporting Lacks Clinical Predictive Value For Live Birth in a Multisite, Double-Blinded Study with Independent Validation.
In a large, double-blinded, non-selection study with independent validation, putative mosaicism (ICN) was associated with only a modest reduction in live birth and did not improve predictive models. Routine reporting of mosaicism offered no clinical benefit and should not guide embryo selection in IVF.
Impact: This study challenges a widely adopted laboratory reporting practice in IVF and provides high-level evidence that mosaic calls do not improve clinical decision-making, potentially reducing embryo discard and improving access to transfer.
Clinical Implications: Clinicians should avoid deprioritizing or discarding embryos solely based on putative mosaicism; counseling and embryo selection should rely on established clinical and embryological factors rather than ICN labels.
Key Findings
- Among 9,828 SETs, 14.4% had ICN (8.8% segmental, 5.6% whole-chromosome) when unblinded post-transfer.
- Live birth was modestly lower with ICN vs euploid (53.2% vs 60.0%; adjusted OR 0.79), driven by high-level ICN.
- Adding ICN to predictive models did not improve discrimination (AUC 0.552 vs 0.555).
- Miscarriage, obstetric, and neonatal outcomes were comparable across groups.
Methodological Strengths
- Multisite, double-blinded, non-selection design minimizing selection and reporting biases.
- Large sample with independent international validation enhances generalizability.
Limitations
- Platform- and laboratory-specific definitions of ICN/mosaicism may limit transferability to other technologies.
- Observational non-selection design is not randomized; residual confounding cannot be fully excluded.
Future Directions: Standardize mosaicism definitions across platforms; evaluate cost, access, and patient-reported outcomes when de-emphasizing mosaic reporting; explore embryo self-correction biomarkers beyond ICN.
BACKGROUND: Preimplantation genetic testing for aneuploidy (PGT-A) is used to improve in vitro fertilization (IVF) outcomes by identifying embryos with lethal chromosomal abnormalities that impair development or lead to pregnancy loss. The adoption of next-generation sequencing (NGS) has enabled detection of intermediate copy number (ICN) deviations, often interpreted as putative mosaicism, whose clinical significance remains uncertain. OBJECTIVE: To determine whether reporting putative mosaicism based on ICN improves the prediction of reproductive outcomes and should influence embryo selection in clinical practice. STUDY DESIGN: We conducted a large, multisite, double-blinded, non-selection study across U.S. fertility clinics (February 2020-October 2022), including 9,828 single-embryo transfers (SETs) from 7,564 IVF cycles. Findings were independently validated using 5,487 euploid SETs from European clinics (May 2022-March 2024). ICN status was unblinded only after embryo transfer, allowing unbiased comparison between embryos that would have been classified as euploid or mosaic with our platform. The primary outcome for investigation in the study was live birth rate, defined as delivery after 24 weeks (gestational age). RESULTS: After unblinding the ICN status post-transfer, 84.7% (n = 8,328) of embryos were negative for ICN (euploid), while 8.8% (n = 864) exhibited segmental ICN and 5.6% (n = 562) showed whole-chromosome ICN within the current clinical and laboratory setting. A modest but statistically significant difference in live-birth rate was observed between euploid embryos and those with ICN (60.0% vs 53.2%; adjusted OR 0.79, 95% CI 0.70-0.89), primarily driven by the small subset of embryos with high-level ICN (P < 0.001, OR 0.61, 95% CI 0.49-0.75). However, ICN did not enhance predictive models incorporating established clinical and embryological factors (AUC = 0.552 vs 0.555; all P > 0.05). Miscarriage, obstetric, and neonatal outcomes were comparable across groups. CONCLUSION: Although the presence of high-level ICN in the TE biopsy was associated with a modest reduction in live-birth rate, because of its low incidence and limited effect size, mosaic reporting did not contribute to a meaningful improvement in clinical outcomes. In our clinical and laboratory setting, reporting putative mosaicism provides no clinical benefit and should not guide embryo selection in routine IVF practice.
3. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050.
The 11th IDF Diabetes Atlas estimates that 11.11% of adults (589 million) live with diabetes in 2024, projected to 12.96% (853 million) by 2050, with higher prevalence in men, urban areas, and middle-income countries. These standardized, country-level estimates underscore the need for tailored prevention and control strategies.
Impact: Provides harmonized, globally comparable prevalence estimates and projections to 2050 for policy planning, resource allocation, and benchmarking across countries.
Clinical Implications: Supports national screening, prevention, and health system planning with stratification by sex, age, urbanicity, and income level; informs prioritization of interventions in rapidly urbanizing and middle-income settings.
Key Findings
- Global adult diabetes prevalence in 2024 is 11.11% (589 million), projected to 12.96% (853 million) by 2050.
- Prevalence is higher in males (11.55%) than females (10.68%) and in urban (12.26%) versus rural (9.23%) settings.
- Middle-income countries have the highest prevalence (11.46%), followed by high- and low-income countries.
- Prevalence peaks at ages 75–79 (24.79%) and remains high above 65 years (23.72%).
Methodological Strengths
- Large-scale synthesis of 246 studies with standardized logistic modeling across 215 countries.
- Stratification by sex, age bands, and urban-rural residence with national standardization.
Limitations
- Extrapolation for countries lacking in-country data may introduce uncertainty.
- Estimates are prevalence-based; incidence, complications, and glycemic control are not directly assessed.
Future Directions: Integrate incidence, complications, and treatment access into future iterations; improve in-country surveillance to reduce extrapolation uncertainty; assess impacts of prevention policies longitudinally.
BACKGROUND: Diabetes is a major global cause of morbidity and mortality. The aim of the 11th edition of the International Diabetes Federation (IDF) Diabetes Atlas is to provide national, regional, and global diabetes prevalence estimates for 2024, with projections to 2050. METHODS: Diabetes (diagnosed and undiagnosed) prevalence among adults aged 20-79 years was estimated in 215 countries and territories, using 246 studies conducted between 2005 and 2024. Studies were filtered by sample size, diagnostic method, study year, representativeness, and publication type. Logistic regression generated 5-year age-specific prevalence estimates stratified by sex and urban-rural location. These estimates were aggregated and standardised to national population distributions to generate national, regional, and global estimates. Extrapolation was applied in countries without in-country data based on others of similar income, geography, ethnicity, and language. FINDINGS: In 2024, diabetes affected 11·11% (95% uncertainty interval 11·05-11·17) of the global adult population, corresponding to 589 million adults (587-591), and is projected to affect 12·96% (12·91-13·02) and 853 million (851-856) people aged 20-79 years by 2050. Prevalence peaked at 24·79% (23·53-26·05) among those aged 75-79 years and was 23·72% (23·67-23·77) in adults aged >65 years. Prevalence was higher in males than females (11·55% [11·43-11·66] vs 10·68% [10·57-10·79]) and in urban than rural areas (12·26% [12·14-12·38] vs 9·23% [9·15-9·31]). Middle-income countries had the highest prevalence (11·46% [11·30-11·63]), followed by high-income (10·21% [9·91-10·50]) and low-income (7·47% [7·17-7·76]) countries. INTERPRETATION: In 2024, one in nine adults worldwide was living with diabetes. The number of adults with diabetes in 2024 exceeded 500 million and is projected to rise to close to 900 million by 2050. As the diabetes epidemic has continued unchecked since the turn of the millennium, stronger efforts are needed to slow its progression, with strategies tailored appropriately across countries and population groups. FUNDING: Sanofi, Novo Nordisk, MSD.